Can you explain the mechanism of action of Givastomig, especially its unique conditional activation mechanism at the tumor sites and how it targets tumors with a wide range of Claudin 18.2 (CLDN18.2) expression?

Based on the data from the recently presented ESMO abstract, how does Givastomig's efficacy compare to other treatments for solid tumors?

Are there specific outcomes, like the partial responses observed in gastroesophageal cancer patients, that stand out in its effectiveness?

Given that Givastomig has shown encouraging monotherapy activity in heavily pre-treated patients, how does it address the unmet medical needs in solid tumor therapy?

From the data presented, how would you characterize the safety profile of Givastomig? Were there any significant adverse events or side effects that clinicians should be aware of?

The trial included patients with a wide range of CLDN18.2 expression. How significant are the findings related to the different levels of CLDN18.2 expression, and what implications might they have for the broader solid tumor patient population?

What are your expectations for the global reception and potential adoption of Givastomig (mono- and combo-therapy)?

Given the ongoing medical advancements in solid tumor treatment and the potential of bispecific antibodies, where do you position Givastomig in the broader treatment paradigm for solid tumors?

Considering the challenges in treating solid tumors, especially in heavily pre-treated patients, how transformative do you believe Givastomig could be in changing the standard of care for these patients?